

Xinmin Nie · Bicheng Zhang · Xiaoling Li
Juanjuan Xiang · Bingyi Xiao · Jian Ma · Ming Zhou
Shiguo Zhu · Hongbin Lu · Rong Gui · Shourong Shen
Guiyuan Li

Cloning, expression, and mutation analysis of NOR₁, a novel human gene down-regulated in HNE₁ nasopharyngeal carcinoma cell line

Received: 10 October 2002 / Accepted: 17 April 2003 / Published online: 18 June 2003
© Springer-Verlag 2003

Abstract Purpose: To investigate cloning, expression, and mutation analysis of the putative candidate tumor suppressor gene related with nasopharyngeal carcinoma (NPC). **Methods:** We studied the expression profiles in the NPC cell line HNE₁ with the normal nasopharyngeal epithelial cell as control by using cDNA array representing 11,000 cDNA clusters. EST W95442 was found down-regulated in HNE₁. Subsequently, the corresponding gene sequence including this EST was established by cDNA cloning and the RACE (rapid amplification of cDNA end) procedure. The expression pattern of this gene was examined by using Northern blot analysis in various human tissues. Furthermore, we screened the mutations of the coding sequence of the gene using reverse transcription-polymerase chain reaction and single-strand conformation polymorphisms (RT-PCR-SSCP) as well as direct sequencing analysis. **Results:** A novel gene (GenBank accession No. AF462348) was cloned and named NOR₁ standing for oxidored-nitro domain-containing protein 1 (Human Gene Nomenclature Committee-approved symbol). Northern blot analysis revealed that the NOR₁ gene had two transcripts (1.2 kb, 1.6 kb), and expressed ubiquitously in human tissues. Moreover, a Glu58Gly mutation in the exon 1 of NOR₁ was detected in two of 25

NPC biopsies. **Conclusions:** We cloned a novel gene NOR₁, and the Glu58Gly polymorphism of NOR₁ may be involved in the development and/or progression of NPC suggesting that NOR₁ could be a candidate tumor repressor gene related with NPC.

Keywords Nasopharyngeal carcinoma · Gene cloning · Mutation analysis

Introduction

Nasopharyngeal carcinoma (NPC) is an endemic cancer with a very high incidence in south-eastern China and North Africa (Hildesheim et al. 1993; Deng et al. 1998). There is a large body of evidence demonstrating that the intake of salted food and EBV infection are a major cause of the high incidence of NPC in these geographical regions (Yu et al. 1986; Poirier et al. 1989; Claudio et al. 2000). Several studies have shown that some samples of salted-fish contained relatively high levels of volatile nitrosamines, all of which induce tumors in the nasal cavities of experimental animals (Druckrey et al. 1967; Magee et al. 1976; Ward et al. 2000). Human are exposed through ingestion or inhalation of nitrosamines from the environment and the endogenous nitrosation of amino precursors in the body. In vivo mechanisms for the formation of nitrosamines may involve chemical and enzyme nitrosation, especially dependent on the presence of nitrate reductase and nitroreductase (Calmels et al. 1987; Zou et al. 1994; Mirvish et al. 1995).

As a high-throughput screening method, cDNA/EST array is an effective approach to finding new genes associated with diseases (Tomasinin et al. 2001). By means of the cDNA array, expression difference was detected by hybridization with cDNA probes from NPC cell line HNE₁ compared with normal nasopharyngeal epithelial cell in our earlier work. The down-regulated ESTW95442 was chosen because of further confirmation using Northern blot analysis. Subsequently, the

This work is supported by: (1) Chinese High Tech R&D Program, No. 2001AA221031; (2) Chinese National Key Program on Basic Research, No. G1998051008; and (3) National Natural Science Foundation of China, grants 30100217

X. Nie · B. Zhang · X. Li · J. Xiang · B. Xiao · J. Ma
M. Zhou · S. Zhu · H. Lu · G. Li (✉)
Cancer Research Institute of Xiang-Ya School of Medicine,
Central South University, 88 Xiangya Road,
410078 Changsha, Hunan, P.R. China
E-mail: ligy@xymu.net
Tel.: +86-731-4805383
Fax: +86-731-4471289

X. Nie · R. Gui · S. Shen
The 3rd Xiang-Ya Hospital of Central South University,
Changsha, Hunan, P.R. China

corresponding full-length cDNA was isolated and characterized (GenBank Accession number: AF462348). Here we describe the cloning and mutation analysis of this gene, designated NOR₁ standing for the oxidored-nitro domain-containing protein from human tissue (HUGO Gene Nomenclature Committee approved symbol).

Materials and methods

Specimens

Primary NPC biopsies were collected from Xiangya Hospital, Central South University, Changsha, Hunan, China. All NPC tumor biopsy specimens were classified histopathologically as primary nasopharyngeal tumors (NPC). None of the patients had received any chemo- or radiotherapy prior to biopsy. The primary tumor biopsies were snap-frozen in liquid nitrogen and stored at -80 °C for subsequent RNA extraction. The NPC cell line HNE₁ was grown as monolayer in RPMI 1640 medium supplemented with 10% fetal bovine serum.

Bioinformatics analysis

Database search was carried out using BLAST and Swiss-Prot. Domain search was performed with CDD (conserved domain database). All bioinformatic tools, including the open reading frame (ORF) identification mentioned in this paper, can be found as entries at ExPASY molecular biology WWW server of the Swiss institute of bioinformatics (www.expasy.ch).

5'RACE and clone sequencing

RACE was carried out with the Marathon-Ready brain cDNA RACE kit and Advantage PCR kit (Clontech, Palo Alto, Calif., USA) as described by the manufacturer. The gene-specific primer1 (GSP₁) (5'-CTCGGATGAATCCCTTGATGGTA-3') was 162–185 bp of cDNA clone 4816622 from the 5' end. The GSP₁ was used in combination with the adapter primer AP₁ to amplify the 5' end of the gene. The PCR amplification was performed for 32 cycles at 94 °C for 30 s and 72 °C for 4 min in a reaction volume of 50 µl according to the manufacturer's protocol. These PCR products were reamplified using a nested GSP₂ (5'-GCTGGAAGCTC CCCTGCAGAGAGA-3') and adapter primer AP₂. The reaction conditions were identical to first-round amplification. The final RACE product were subcloned to the PGEM-T system (Promega) and sequenced. All sequencing was performed on an ABI377 DNA sequencer (Perkin-Elmer, USA).

Expression analysis

For Northern blot analysis, a human multi-tissue Northern blot (Clontech) was hybridized with the 450 bp PCR product corresponding to the sequence of the coding region of NOR₁ according to the manufacturer's specifications. Probes were labeled with [³²P] dATP using the Random primer kit (Boehringer, Mannheim). The filter was washed to a final stringency of 1×SSC, 0.1% SDS at 60 °C and exposed to film (Eastman Kodak) for 5 days at -80 °C.

Mutation analysis using RT-PCR-SSCP

cDNA synthesis was performed using 2 µg of total tissue RNA and 500 ng of oligo (dT) primer, using Expand Reverse transcriptase (Roche, Meylan France) according to manufacturer's recommen-

ations. PCR amplification was performed with the aid of the following primers: S₁ (sense; 5'-ATGGTCAGGCCAAATC) and AS₁ (antisense; 5'-AAGTTCAAGAAGAGCAGC); S₂ (sense; 5'-AGCACCATGTGCGGTGCG) and AS₂ (antisense; 5'-TAGAGCTCTTGAGGCTTG); S₃ (sense; 5'-AATAGAAAGTTTATGG) and AS₃ (antisense; 5'-ACACAGCAATACTTGAT); S₄ (sense; 5'-ACCTGATGACCATGGCT) and AS₄ (antisense; 5'-TCGGATGTGCGGTCTT); S₅ (sense; 5'-ATCCGGCAGACACTCCT) and AS₅ (antisense; 5'-TGGGTGCAGGGACATAG); S₆ (sense; 5'-ATGAATTCAAGCATGGTGG) and AS₆ (antisense; 5'-TCTTCTTTAGCAAGAGG). PCR amplification was carried out in the presence of 10% glycerol and consisted of 35 cycles at 94 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s, with a 10-min extension at 72 °C after the last cycle. Non-radioactive single strand confirmation polymorphism (SSCP) analysis was performed on all PCR products. Ten microliters of PCR product were mixed with an equal volume of denaturing solution (96% formamide, 20 mM EDTA, 0.05% bromophenol blue); the mixture was incubated at 98 °C for 10 min and rapidly quenched in ice. The samples were then applied to 8–10% polyacrylamide slab gels and electrophoresed at 150 V for 2–6 h. Gels were then silver stained. PCR fragments displaying SSCP abnormal patterns were submitted to direct sequencing.

Results

Identification and cloning of the full-length cDNA of NOR₁

In a previous work, we used the cDNA array representing 11,000 cDNA to compare the expression profiles between HNE₁ cell line and normal nasopharyngeal epithelial cell. One EST (GenBank entry: w95442) was found with a high level of expression in primary culture of normal nasopharyngeal epithelial cells, whereas it was very low in NPC cell line HNE₁. The result of Northern blot hybridization of this EST (Fig. 1) was consistent with that of cDNA array analysis. This suggested that this EST might indicate a novel gene related with nasopharyngeal carcinoma, so we characterized it more fully.

To obtain the full-length cDNA, we obtained the cDNA clone 4816622 corresponding to the EST w95442. The sequencing of this clone includes an insert about 1.4 kb in length, a putative open reading frame (ORF) from nt 16 to 1107, and a poly(A) tail at the 3' end, but




Fig. 1 Down-regulated expression of NOR₁ in NPC cell line HNE₁ compared with that in normal nasopharyngeal epithelial cell. Lanes: 1, normal nasopharyngeal epithelial cell; 2, NPC cell line HNE₁. GADPH served as controls for RNA quality




Fig. 2 Expression of NOR₁ mRNA in normal human tissues. A multitissue Northern blot (Clontech) was probed with NOR₁ cDNA. The same blot was rehybridized with a β -actin probe, as a control for RNA loading and transfer

no in-frame stop codon at the 5' end. When this cDNA clone was used as a probe in the Northern blot, double transcripts (1.6 kb, 1.2 kb) were observed in all tissues studied and high expression levels were detected in skeletal muscle and heart (Fig. 2). Because the large transcript was about 200 bp longer than the cDNA clone insert, we used the Marathon-Ready brain cDNA RACE approach to find the 5' end as described above. Fortunately, the 350-bp fragment of RACE product was obtained and incorporated into the 5' sequence of the cDNA clone 4816622, and a 1601-bp gene sequence was generated (GenBank Accession No. AF462348).

Bioinformatics analysis of the sequence of NOR₁ cDNA

By searching NOR₁ gene in the Human Genome Database, we found that the NOR₁ is localized on chromosome 1p34.2 and has 10 exons and spans 33.4 kb of the genomic DNA. In addition, there was a putative open reading frame (ORF) from 33nt to 1298nt (Fig. 3) in NOR₁. The predicted protein has a theoretical molecular mass of 48 kD and a calculated isoelectric point of 5.78. The initiation codon (ATG in bold type) is surrounded by a translation initiation context (Kozak 1989). When NOR₁ was analyzed by search for functional domain using the bioinformatics tool (available at <http://www.ncbi.nlm.nih.gov/Structure/cdd/>), the result revealed the presence of an oxidored-nitro domain in NOR₁. Interestingly, the deduced amino acid sequence of NOR₁ shares 39% identity with that of "classical" nitroreductase of *Salmonella typhimurium* (Fig. 4), so we proposed that NOR₁ is a novel nitroreductase derived from human tissue. In addition, the PROSITE database identified two possible cAMP and cGMP-dependent protein kinase phosphorylation sites, five Casein Kinase II phosphorylation sites, and four N-myristoylation sites in NOR₁.




Fig. 3 Nucleotide sequence and the deduced amino acid sequence of the NOR₁ cDNA. The ATG start codon, TAG stop codon, and poly(A) tail are shown in bold. The tandem oxidored-nitro domains are underlined

Mutation analysis of the coding region of NOR₁ using RT-PCR-SSCP

We searched for mutations in the NOR₁ coding sequence using an RT-PCR approach. RNAs extracted from the 25 tumor biopsies were reverse-transcribed and cDNA used as a template for subsequent PCR amplification. Then, we used PCR-SSCP to detect mutations in the coding sequence of NOR₁. To this end, six overlapping PCR fragments were designed in order to

Query: 169 RDSPTILQQVDETLRQLTEIYGGLSAG---EFQLIRQTLLEIFFQDLHIRVSMFLKDKVQN 225
 R SP LQ + LRQ E+ L AG E QL TLL +D H +S FL+ + +
 Sbjct: 196 RHISPLALQAAKQALRQSQEV--ALQAGLAQERQLF--TLAATEDRHEGISAFLQKRTPD 251

Query: 226 NNGR 229
 GR
 Sbjct: 252 FKGR 255

Fig. 4 Comparison of the amino acid sequence of NOR₁ with those of "classical" nitroreductase of *Salmonella typhimurium*. *Query* the amino acid sequence of NOR₁; *Sbjct* the amino acid sequence of "classical" nitroreductase




Fig. 5A–C Mutations in the NOR₁ gene detected by PCR-SSCP analysis in NPC samples. **A** PCR-SSCP analysis of exon 1 of the NOR₁ gene from various NPC specimens and genomic placenta DNA as control (CT); **B** wild type sequence of NOR₁ from nt 241 to 264; **C** mutation sequence of NOR₁ from nt 241 to 264

amplify products with an average size of 200 bp. PCR-SSCP analysis of exon 1 showed the presence of two different migration patterns: the wild-type SSCP pattern exhibited by both the control placenta DNA and the sample NPC1, while the mutated pattern was found in the samples NPC7 and NPC18 (Fig. 5A). Interestingly, the two tumor samples NPC7 and NPC18 that exhibited the same patterns for exon 1 were shown to have the same mutations. The mutation corresponded to a GAG → GGG transition (Fig. 5B,C) at position 173 (exon 1) leading to the change of Glu into Gly at the amino acid residue 58.

Discussion

This paper reports the cloning and the mutation analysis of a novel gene NOR₁. NOR₁ gene encodes a putative protein of 421 amino acids with a theoretical molecular mass of 48 kD and a calculated isoelectric point of 5.78. The Northern-blot analysis showed the gene was expressed ubiquitously in human tissues. Because the predicted amino acid sequence has no significant homology to known proteins we were unable to speculate on the function of this protein. However, some bioinformatics tools employed in the PROSITE database identified an important oxidored-nitro domain in NOR₁ and we designated the novel gene as NOR₁ standing for oxidored-nitro contained protein from human tissue, which has been approved by HUGO Gene nomenclature Committee.

There is much evidence showing that nitrate reductases and nitroreductases are important enzymes during the formation of nitrosamines by their nitrosation activity (Ayanaba et al. 1973; Mills et al. 1976; Calmels et al. 1987). In addition, "classical" nitroreductase of *S. typhimurium* is a flavoprotein that catalyzes the reduction of nitroaromatics to metabolites that are toxic, mutagenic, or carcinogenic (Watanabe et al. 1998). The activity of "classical" nitroreductase to reduce a range of dinitrophenylcarboxamides has highlighted its potential usefulness in gene therapy for the tumor-selective activation of cytotoxic alkylating drugs (especially CB1954/NTR system) and has since been used in several prodrug approaches such as ADEPT (antibody-directed enzyme prodrug therapy), and GDEPT (gene-directed), (Parkinson et al. 2000; Plumb et al. 2001; Wilson et al. 2002). NOR₁ may be a novel member of nitroreductases which exhibit low substrate specificity but have the similar function of reducing nitro (Parkinson et al. 1998). Since NOR₁ may be a nitroreductase gene derived from human tissue, the functional study of NOR₁ may open the door to the study of relating environmental factors with genetic factors during the carcinogenesis of NPC.

Since only NOR₁ mRNA levels were measured in this study, the slow expression level observed could be due to a slow turnover of this messenger or its increased stability. Further, it is not known whether the NOR₁ protein levels are affected by the mutation or single nucleotide polymorphisms (SNP) of the NOR₁ gene. Investigations are currently underway to determine NOR₁ protein levels in nasopharyngeal carcinoma cell line HNE₁ and normal nasopharyngeal epithelial cell. Mutations (Glu58Gly) were found to occur in the coding region of NOR₁, which is most likely to influence the function of the gene. The hypothesis that mutation in the NOR₁ gene has an influence on the protein level or enzyme activity must certainly be extended further as has been suggested (Williams et al. 2001). Furthermore, chromosome 1p is the most frequent loss loci of genetic material by comparative genomic hybridization (CGH) in primary NPC biopsies (Guo et al. 1999; Yan et al.

2001; Li et al. 2001). Since the NOR₁ gene is located on 1p34.2 and has the genetic changes in the coding region, NOR₁ might be a good candidate tumor suppressor gene or related gene in nasopharyngeal tumorigenesis.

Large screening of the NOR₁ gene for mutations in patients from high-risk regions of NPC would help to clarify the relationship between the NOR₁ gene and NPC genesis. This would also help to clarify the role of dietary factors and/or EBV infections together with tumor suppressor gene mutations in NPC pathogenesis. The hypothesis that mutations in the NOR₁ gene are involved in NPC pathogenesis must be certainly extended further. A study examining a large number of NPC biopsies, especially in pedigrees of the NPC family, would help to better investigate the role of NOR₁ in nasopharyngeal tumorigenesis. Additionally, because identical mutations were found in different tumor biopsies, further investigation would be worthwhile on the possible presence of a mutational "hot spot" in NPC, which could be useful to develop a rapid diagnostic and/or prognostic tool for these patients.

Acknowledgements This work is supported by (1) Chinese High Tech R&D Program, No.2001AA221031; (2) Chinese National Key Program on Basic Research, No.G1998051008; (3) National Natural Science Foundation of China, grants: 30100217.

References

- Ayanaba A, Alexander M (1973) Microbial formation of nitrosamines in vitro. *Appl Microbiol* 25:862–868
- Calmels S, Ohshii H, McCoy E, et al (1987) Biochemical studies on the catalysis of nitrosation by bacteria. *Carcinogenesis* 8:1085–1088
- Claudio PP, Howard CM, Fu Yan (2000) Mutations in the retinoblastoma-related gene RB/p130 in primary nasopharyngeal carcinoma. *Cancer Res* 60:8–12
- Deng LW, Jiang L, Tan GL, Li GY (1998) A common region of allelic loss on chromosome region on 3p25.3–26.2 in nasopharyngeal carcinoma. *Gene Chromosome Cancer* 23:21–25
- Druckrey H, Pressmann R, Ivankovic S (1967) Organotrope carcinogene Wirkungen bei 65 verschiedenen N-nitroso-Verbindungen an BD-Ratten. *Z.Krebsforsch* 69:103–01
- Guo Y, Fan Y, Liang QW, et al (1995) Chromosome aberrations in 47 nasopharyngeal carcinoma. *Chinese J Cancer Res* 18:5–8
- Hildesheim A, Levin P (1993) Etiology of nasopharyngeal carcinoma: a review. *Epidemiol Rev* 15:446–485
- Kozak M (1989) The scanning model for translation: an update. *J Cell Biol* 108:229–24
- Li ZH, Wan L, Zhang XH, et al (2001) Chromosomal aberration analyzed by comparative genomic hybridization in nasopharyngeal carcinoma. *Chin J Med Genet* 18:336–342
- Magee PN, Montesano R, Pressmann R (1976) N-nitroso compounds and related carcinogens. *Chem Carcinogens* 173:491–625
- Mills AL, Alexander M (1976) N-Nitrosamine formation by cultures of several microorganisms. *Appl Environ Microbiol* 31:892–895
- Mirvish SS (1995) Role of N-nitroso compounds(NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposure to NOC. *Cancer Lett* 97:271
- Parkinson GN, Skelly JV, Neidle S (2000) Crystal structure of FMN-dependent nitroreductase from *Escherichia coli* prodrug-activating enzyme. *J Med Chem* 43:3624–3631
- Plumb JA, Bilisland A, Kakani R (2001) Tolomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. *Oncogene* 20:7797–7803
- Polier S, Bouvier G, Malaveille C (1989) Volatile nitrosamine levels and genotoxicity of food samples from high-risk areas for nasopharyngeal carcinoma before and after nitrosation. *Int J Cancer* 44:1088–1094
- Tomasinin R, Samir Azizi A, Vaccaro MI (2001) Molecular and function characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. *J Biol Chem* 47:44185–44192
- Ward MH, Pan WH, Cheng YJ, et al (2000) Dietary exposure to nitrite and nitrosamines and risk of nasopharyngeal carcinoma in TaiWan. *Int J Cancer* 86:603–609
- Watanabe M, Nishino T, Takio K, et al (1998) Purification and characterization of wild-type and mutant "classical" nitroreductase of *Salmonella typhimurium*. *J Biol Chem* 273:23922–23928
- Williams JA (2001) Single nucleotide polymorphism, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. *Carcinogenesis* 22:209–214
- Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA (2002) Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. *Cancer Res* 62:1425–1432
- Yan J, Fang Y, Liang Q, et al (2001) Frequent chromosomal gain of 4q and loss of 1p in primary nasopharyngeal carcinoma. *Chin J Oncol* 23:208–210
- Yu MC, Ho J, Lai SH, et al (1986) Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. *Cancer Res* 46:956–961
- Zou XN, Lu SH, Liu B, et al (1994) Volatile N-nitrosamines and their precursors in Chinese salted fish—a possible etiological factor for NPC in China. *Int J Cancer* 59:155–158